Neway T, Boulouis H J, Thibault D, Pilet C
Institut d'Immunologie animale et comparée, Ecole nationale vétérinaire d'Alfort, Maisons-Alfort.
C R Acad Sci III. 1992;315(1):13-9.
Intraperitoneal administration of polar glycopeptidolipids extracted from Mycobacterium chelonae (GPLp-Mc) has led to reversal of Doxorubicin-induced leucopenia in a manner comparable to that effected by GM-CSF administered in a dose of 100 IU (2.5 micrograms/kg). The mode of action and the toxicity of this product are being studied. Results obtained on the mouse indicate that it would be worthwhile to undertake tests in man aimed at studying the effect of GPLp-Mc on chemotherapy- and radiotherapy-induced leukopenias, once toxicological studies have been carried out.
腹腔注射从龟分枝杆菌中提取的极性糖肽脂（GPLp-Mc）可使阿霉素诱导的白细胞减少症得到逆转，其效果与以100国际单位（2.5微克/千克）剂量给予的粒细胞巨噬细胞集落刺激因子（GM-CSF）相当。目前正在研究该产品的作用方式和毒性。在小鼠身上获得的结果表明，一旦进行了毒理学研究，就值得在人体中进行试验，以研究GPLp-Mc对化疗和放疗引起的白细胞减少症的影响。
